Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2006

View Archived Issues

AEterna Zentaris presents pipeline round-up

Orphan drug designation for Valortim in treatment of anthrax infection

Phase III efficacy trials begin for Technosphere Insulin

Priority review for TMC-114

Infinity and Novartis collaborate on Bcl-2 family inhibitors

Nereus closes second tranche of financing

Velcade studied in combination with pemetrexed for advanced NSCLC

Enrollment completed in phase I study of Chemophase for bladder cancer

Endovasc submits phase IIIa Liprostin protocol to FDA

Positive results for CX-717 in adults with ADHD

Positive Advisory Committee vote for Cubicin sNDA

Anti-rabies monoclonal antibody combination effective in vitro and in vivo

Mometasone nasal spray reduces nasal polyps

Intraperitoneal chemotherapy beneficial in patients with ovarian cancer

Safety, pharmacokinetics and comparative efficacy of BAY-59-7939 evaluated

LS-104 targets mutated Flt3 to provide enhanced anti-AML activity

Novel agents for nephritis disclosed in recent Shionogi patent

Xyrem launched for excessive daytime sleepiness in narcolepsy patients

Dasatinib NDA accepted for priority review

Recent patents cover therapeutic agents for neurological disorders

Novel antidiabetic agents disclosed in recent patents

S-236 cream may be used to promote barrier repair in atopic dermatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...